These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35257905)

  • 21. Procalcitonin for antimicrobial stewardship among cancer patients admitted with COVID-19.
    Dagher H; Chaftari AM; Mulanovich P; Jiang Y; Hachem R; Malek AE; Borjan J; Viola GM; Raad I
    Elife; 2022 Dec; 11():. PubMed ID: 36541589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Community-acquired and hospital-acquired bacterial co-infections in patients hospitalized with Covid-19 or influenza: a retrospective cohort study.
    Jorda A; Gabler C; Blaschke A; Wölfl-Duchek M; Gelbenegger G; Nussbaumer-Pröll A; Radtke C; Zeitlinger M; Bergmann F
    Infection; 2024 Feb; 52(1):105-115. PubMed ID: 37326938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of respiratory bacterial co-infection and assessment of empirical antibiotic treatment in patients with COVID-19 at hospital admission.
    Antuori A; Giménez M; Linares G; Cardona PJ
    Sci Rep; 2023 Nov; 13(1):19302. PubMed ID: 37935785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An observational cohort study of bacterial co-infection and implications for empirical antibiotic therapy in patients presenting with COVID-19 to hospitals in North West London.
    Wang L; Amin AK; Khanna P; Aali A; McGregor A; Bassett P; Gopal Rao G
    J Antimicrob Chemother; 2021 Feb; 76(3):796-803. PubMed ID: 33185241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elucidating the role of procalcitonin as a biomarker in hospitalized COVID-19 patients.
    Cowman K; Rossi J; Gendlina I; Guo Y; Liu S; Szymczak W; Forest SK; Wolgast L; Orner E; Bao H; Cervera-Hernandez ME; Ceniceros A; Thota R; Pirofski LA; Nori P
    Diagn Microbiol Infect Dis; 2022 Aug; 103(4):115721. PubMed ID: 35635888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Retrospective Study of Coinfection of SARS-CoV-2 and Streptococcus pneumoniae in 11 Hospitalized Patients with Severe COVID-19 Pneumonia at a Single Center.
    Rodriguez-Nava G; Yanez-Bello MA; Trelles-Garcia DP; Chung CW; Egoryan G; Friedman HJ
    Med Sci Monit; 2020 Nov; 26():e928754. PubMed ID: 33188161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of a multiplex PCR screening approach to identify community-acquired bacterial co-infections in COVID-19: a multicenter prospective cohort study of the German competence network of community-acquired pneumonia (CAPNETZ).
    Rothe K; Spinner CD; Panning M; Pletz MW; Rohde G; Rupp J; Witzenrath M; Erber J; Eberhardt F; Essig A; Schneider J;
    Infection; 2021 Dec; 49(6):1299-1306. PubMed ID: 34687426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Invasive Pneumococcal Disease and Risk of Pneumococcal Coinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Prospective National Cohort Study, England.
    Amin-Chowdhury Z; Aiano F; Mensah A; Sheppard CL; Litt D; Fry NK; Andrews N; Ramsay ME; Ladhani SN
    Clin Infect Dis; 2021 Mar; 72(5):e65-e75. PubMed ID: 33196783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of respiratory bacterial infections on mortality in Japanese patients with COVID-19: a retrospective cohort study.
    Nakagawara K; Kamata H; Chubachi S; Namkoong H; Tanaka H; Lee H; Otake S; Fukushima T; Kusumoto T; Morita A; Azekawa S; Watase M; Asakura T; Masaki K; Ishii M; Endo A; Koike R; Ishikura H; Takata T; Matsushita Y; Harada N; Kokutou H; Yoshiyama T; Kataoka K; Mutoh Y; Miyawaki M; Ueda S; Ono H; Ono T; Shoko T; Muranaka H; Kawamura K; Mori N; Mochimaru T; Fukui M; Chihara Y; Nagasaki Y; Okamoto M; Amishima M; Odani T; Tani M; Nishi K; Shirai Y; Edahiro R; Ando A; Hashimoto N; Ogura S; Kitagawa Y; Kita T; Kagaya T; Kimura Y; Miyazawa N; Tsuchida T; Fujitani S; Murakami K; Sano H; Sato Y; Tanino Y; Otsuki R; Mashimo S; Kuramochi M; Hosoda Y; Hasegawa Y; Ueda T; Takaku Y; Ishiguro T; Fujiwara A; Kuwahara N; Kitamura H; Hagiwara E; Nakamori Y; Saito F; Kono Y; Abe S; Ishii T; Ohba T; Kusaka Y; Watanabe H; Masuda M; Watanabe H; Kimizuka Y; Kawana A; Kasamatsu Y; Hashimoto S; Okada Y; Takano T; Katayama K; Ai M; Kumanogoh A; Sato T; Tokunaga K; Imoto S; Kitagawa Y; Kimura A; Miyano S; Hasegawa N; Ogawa S; Kanai T; Fukunaga K;
    BMC Pulm Med; 2023 Apr; 23(1):146. PubMed ID: 37101265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bacterial infections in patients with COVID-19: the impact of procalcitonin testing on antibiotics prescription in the real world.
    Lui GC; Cheung CS; Yip TC; Lai MS; Li TC; Wong GL
    BMC Infect Dis; 2024 Jan; 24(1):106. PubMed ID: 38243171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secondary Bacterial Infection and Clinical Characteristics in Patients With COVID-19 Admitted to Two Intensive Care Units of an Academic Hospital in Iran During the First Wave of the Pandemic.
    Pourajam S; Kalantari E; Talebzadeh H; Mellali H; Sami R; Soltaninejad F; Amra B; Sajadi M; Alenaseri M; Kalantari F; Solgi H
    Front Cell Infect Microbiol; 2022; 12():784130. PubMed ID: 35281440
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of antimicrobial use and co-infections among hospitalized patients with COVID-19: a prospective observational cohort study.
    Lingscheid T; Lippert LJ; Hillus D; Kruis T; Thibeault C; Helbig ET; Tober-Lau P; Pfäfflin F; Müller-Redetzky H; Witzenrath M; Zoller T; Uhrig A; Opitz B; Suttorp N; Kramer TS; Sander LE; Stegemann MS; Kurth F
    Infection; 2022 Dec; 50(6):1441-1452. PubMed ID: 35420370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is procalcitonin a part of human immunological response to SARS-CoV-2 infection or "just" a marker of bacterial coinfection?
    Lugito NPH
    Curr Res Transl Med; 2021 May; 69(2):103289. PubMed ID: 33845428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baseline procalcitonin as a predictor of bacterial infection and clinical outcomes in COVID-19: A case-control study.
    Atallah NJ; Warren HM; Roberts MB; Elshaboury RH; Bidell MR; Gandhi RG; Adamsick M; Ibrahim MK; Sood R; Bou Zein Eddine S; Cobler-Lichter MJ; Alexander NJ; Timmer KD; Atallah CJ; Viens AL; Panossian VS; Scherer AK; Proctor T; Smartt S; Letourneau AR; Paras ML; Johannes S; Wiemer J; Mansour MK
    PLoS One; 2022; 17(1):e0262342. PubMed ID: 35025929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Characteristics and Outcome of Hospitalized COVID-19 Patients in a MERS-CoV Endemic Area.
    Barry M; AlMohaya A; AlHijji A; Akkielah L; AlRajhi A; Almajid F; Alsharidi A; Al-Shahrani FS; Alotaibi NH; Alanazi A; Ghonem L; Alhetheel A; Alsubaie S; Memish ZA
    J Epidemiol Glob Health; 2020 Sep; 10(3):214-221. PubMed ID: 32954712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics of COVID-19 patients with bacterial coinfection admitted to the hospital from the emergency department in a large regional healthcare system.
    Lardaro T; Wang AZ; Bucca A; Croft A; Glober N; Holt DB; Musey PI; Peterson KD; Trigonis RA; Schaffer JT; Hunter BR
    J Med Virol; 2021 May; 93(5):2883-2889. PubMed ID: 33448423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence and risk factors for secondary pulmonary infections in patients hospitalized with coronavirus disease 2019 pneumonia.
    Chong WH; Chieng H; Tiwari A; Beegle S; Feustel PJ; Ghalib S; Al-Tarbsheh AH; Jain E; Mullins J; Keenan M; Chopra A
    Am J Med Sci; 2022 Jun; 363(6):476-483. PubMed ID: 33894182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical impact of bacterial co-infection among moderate, severe and critically ill COVID-19 patients in the second referral hospital in Surabaya.
    Asmarawati TP; Rosyid AN; Suryantoro SD; Mahdi BA; Windradi C; Wulaningrum PA; Arifianto MV; Bramantono B; Triyono EA; Rusli M; Rachman BE; Marfiani E; Endraswari PD; Hadi U; Kuntaman K; Nasronudin N
    F1000Res; 2021; 10():113. PubMed ID: 33868645
    [No Abstract]   [Full Text] [Related]  

  • 39. Combination of procalcitonin and C-reactive protein levels in the early diagnosis of bacterial co-infections in children with H1N1 influenza.
    Li Z; He L; Li S; He W; Zha C; Ou W; Hou Q; Wang W; Sun X; Liang H
    Influenza Other Respir Viruses; 2019 Mar; 13(2):184-190. PubMed ID: 30443990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. National surveillance of bacterial and fungal coinfection and secondary infection in COVID-19 patients in England: lessons from the first wave.
    Gerver SM; Guy R; Wilson K; Thelwall S; Nsonwu O; Rooney G; Brown CS; Muller-Pebody B; Hope R; Hall V
    Clin Microbiol Infect; 2021 Nov; 27(11):1658-1665. PubMed ID: 34481722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.